Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt by Zahn, Alexandra et al.
RESEARCH ARTICLE Open Access
Budd-Chiari Syndrome: Long term success via
hepatic decompression using transjugular
intrahepatic porto-systemic shunt
Alexandra Zahn
1*, Daniel Gotthardt
1, Karl Heinz Weiss
1, Götz Richter
2, Jan Schmidt
3, Wolfgang Stremmel
1,
Peter Sauer
1
Abstract
Background: Budd-Chiari syndrome (BCS) generally implies thrombosis of the hepatic veins and/or the
intrahepatic or suprahepatic inferior vena cava. Treatment depends on the underlying cause, the anatomic location,
the extent of the thrombotic process and the functional capacity of the liver. It can be divided into medical
treatment including anticoagulation and thrombolysis, radiological procedures such as angioplasty and transjugular
intrahepatic porto-systemic shunt (TIPS) and surgical interventions including orthotopic liver transplantation (OLT).
Controlled trials or reports on larger cohorts are limited due to rare disease frequency. The aim of this study was to
report our single centre long term results of patients with BCS receiving one of three treatment options i.e.
medication only, TIPS or OLT on an individually based decision of our local expert group.
Methods: 20 patients with acute, subacute or chronic BCS were treated between 1988 and 2008. Clinical records
were analysed with respect to underlying disease, therapeutic interventions, complications and overall outcome.
Results: 16 women and 4 men with a mean age of 34 ± 12 years (range: 14-60 years) at time of diagnosis were
included. Myeloproliferative disorders or a plasmatic coagulopathy were identified as underlying disease in 13
patients, in the other patients the cause of BCS remained unclear. 12 patients presented with an acute BCS, 8 with
a subacute or chronic disease. 13 patients underwent TIPS, 4 patients OLT as initial therapy, 2 patients required
only symptomatic therapy, and one patient died from liver failure before any specific treatment could be initiated.
Eleven of 13 TIPS patients required 2.5 ± 2.4 revisions (range: 0-8). One patient died from his underlying
hematologic disease. The residual 12 patients still have stable liver function not requiring OLT. All 4 patients who
underwent OLT as initial treatment, required re-OLT due to thrombembolic complications of the graft. Survival in
the TIPS group was 92.3% and in the OLT group 75% during a median follow-up of 4 and 11.5 years, respectively.
Conclusion: Our results confirm the role of TIPS in the management of patients with acute, subacute and chronic
BCS. The limited number of patients with OLT does not allow to draw a meaningful conclusion. However, the
underlying disease may generate major complications, a reason why OLT should be limited to patients who
cannot be managed by TIPS.
Background
Budd-Chiari syndrome (BCS) is a rare disorder defined as
a hepatic venous outflow obstruction at any level between
the hepatic veins and the right atrium [1] but generally
implies thrombosis of the hepatic veins and/or the intrahe-
patic or suprahepatic inferior vena cava (IVC). Up to 50%
of all cases of BCS are due to chronic myeloproliferative
disorders like polycythemia vera (PV) [2] or coagulopa-
thies like factor V (Leiden) gene mutation [3-5]. The clini-
cal presentation is highly variable but may be categorized
as acute and perhaps fulminant hepatic failure, as subacute
without evidence of cirrhosis or as chronic with evidence
of portal hypertension and cirrhosis.
Treatment depends on the underlying cause, the ana-
tomic location, the extent of the thrombotic process and
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divided into medical treatment including anticoagulation
and thrombolysis [6-8], radiological procedures such as
angioplasty [9] and transjugular intrahepatic porto-sys-
temic shunt (TIPS) [10-14] and surgical procedures
including porto-systemic shunting (PSS) [15-17] and
orthotopic liver transplantation (OLT) [18,19]. Anticoa-
gulation alone is unlikely to lead to sufficient recanaliza-
tion of occluded vessels, or development of adequate
collateral circulation. However, satisfactory long-term
survival with only medical therapy has been reported
[6,20]. Recent data failed to show a favorable impact of
PSS on survival [17,21], while TIPS has shown encoura-
ging results [11-13,22-25].
This may give rise to redefine the role of OLT which
may now be preserved for patients failing TIPS. The
present treatment recommendations of BCS [26,27] are
not based on randomized studies but on a small number
of retrospective studies [8,25,27] and one prospective
study [20].
The aim of this single centre retrospective study was
to further enlarge the body of patients evaluated with
the intention to allow steady optimization of present
treatment strategies.
Methods
Study design
Patients admitted between 1988 and 2008 with a pri-
mary diagnosis of BCS were enrolled into this retrospec-
tive analysis. All available medical records especially
laboratory data, radiological imaging and procedures,
surgical interventions and discharge letters were
reviewed. All data at the time of diagnosis and of new
treatment were considered. Date of diagnosis was the
date of the first investigation when the criteria for diag-
nosis were fulfilled. BCS was defined following the Eur-
opean network for vascular disorders of the liver (En-
Vie) [28] criteria and the last Baveno consensus based
on imaging showing an obstructed venous outflow tract
[26]. Diagnosis of BCS was made by either Doppler
ultrasonography, magnetic resonance imaging or com-
puterized tomography.
Disease severity was defined as acute, subacute or
chronic. In contrast to the acute disease, the subacute
and chronic forms were assumed to be present for sev-
eral weeks to more than six months prior to clinical
presentation [29].
Different from the last Baveno consensus [26] treat-
ment was only partly applied in a stepwise manner. On
the basis of radiological imaging and the severity of clin-
ical presentation a decision by an experienced interdisci-
plinary team concerning adequate treatment was
reached. This could either be a medical treatment or a
prompt intervention. If patients did not improve on
medical therapy TIPS insertion was performed.
Patients who underwent OLT as initial therapy were
not candidates for TIPS. Two patients were transplanted
before TIPS had been introduced as a treatment option
of BCS, namely in 1988 and 1992. The other patients
had cirrhosis with signs of chronic liver failure in terms
of hepatic encephalopathy and high bilirubin levels so
that liver transplantation was considered essential in
these patients.
Hematological evaluation of hypercoagulable state
To identify a hypercoagulable state as the underlying
etiology of BCS each patient received a comprehensive
hematological evaluation. The latter was performed
stepwise and included antiphospholipid antibodies,
homocysteine levels, testing for factor V (Leiden) and
prothrombin (20210) mutation, APC resistance, ATIII,
protein C and S levels. Patients in whom a myeloproli-
ferative disorder (MPD) like PV or essential thrombocy-
tosis was suspected received a bone marrow biopsy. As
our study begun in 1988, not all of our patients were
screened for the JAK2V617F mutation.
TIPS Technique and OLT
All TIPS were created using standard techniques [30-32]
by insertion of Palmaz stents (Johnson and Johnson
Interventional Systems, Warren, New Jersey), Wallstents
(Schneider, Minneapolis, Minnesota) or covered Viatorr
stents (GORE, Flagstaff, AZ). When a hepatic vein rem-
nant was not present the portal vein was punctured
directly from the IVC [30]. After the TIPS procedure
patients underwent anticoagulation according to the
guidelines [26]. Patients underwent control angiography
3 months after TIPS and in addition if shunt dysfunc-
tion was suspected. An abdominal ultrasound was per-
formed every 6 months. TIPS dysfunction was defined
as an increase in portosystemic gradient above 10 to 12
mmHg and clinical signs of portal hypertension.
In our liver transplantation program the modified pig-
gyback technique by Belghiti [33] has been used as a
routine surgical procedure since 2001. Before 2001, the
so-called piggyback technique had been applied [34,35].
Statistical analysis
Descriptive statistics were provided as mean ± standard
deviation (SD) and as range. The cumulative survival
probability was estimated by the method described by
Kaplan and Meier. All analyses were carried out in
Microsoft Excel and SPSS.
The study protocol conformed to the ethical guide-
lines of the Helsinki Declaration, and was approved by
the ethics committee of the University of Heidelberg.
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Patients characteristics
20 patients, 4 male and 16 female, were included in our
study. Patient age ranged from 14 to 60 with a mean age
of 34 ± 12 years. Patients characteristics are given in table
1. Myeloproliferative disorders (especially PV) were the
cause of BCS in 6 patients, 7 patients had plasmatic coagu-
lation abnormalities, 1 patient took oestrogen medication
as a possible underlying hypercoagulable condition and in
6 patients the aetiology of BCS remained unclear. As not
all of our patients were screened for the JAK2V617F muta-
tion latent MPD may have been missed in several patients.
12 patients presented with acute BCS, 8 with subacute or
chronic disease. 8 patients presented with abdominal pain,
3 with new onset of ascites, 7 with abdominal pain plus
new onset of ascites, 1 with gastrointestinal bleeding plus
ascites and 1 with acute liver failure.
Treatment and outcome
13 patients underwent TIPS (10 women, 3 men) and 4
underwent OLT (3 women, 1 man) as initial therapy.
One of the remaining 3 patients died of fulminant liver
failure rapidly after the initial diagnosis, the other
patients have not had an intervention, yet as their status
was stable under a symptomatic anticoagulation therapy.
In the TIPS group mean age was 36 ± 13 years (range:
20-60 years) and in the transplant group 27 ± 9 years
(range: 14-34 years). 8 of 13 patients in the TIPS group
underwent TIPS within one week after the diagnosis of
BCS was confirmed, 3 patients underwent TIPS within 1
month, 1 patient within 2 months and in 1 patient time
period until TIPS placement was 48 months.
T h ep o r t o - s y s t e m i cp r e s s u r eg r a d i e n tw a sl o w e r e db y
a mean of 21 ± 10 mmHg (range: 6-40 mmHg) in the
13 patients initially treated with TIPS. After a median
Table 1 Baseline Characteristics of all Patients
Patient Underlying diagnosis Clinical presentation Time of
presentation
(year)
Time between primary
diagnosis and
intervention (months)
Relevant
Comorbidities
TIPS Group
1 Unknown Abdominal pain 2006 0 None
2 Polycythemia vera Ascites 2004 0 Thyroidectomy, Schizophrenia
3 Factor V (Leiden) mutation,
protein C deficiency
Abdominal pain and
ascites
2005 0 None
4 Unknown Abdominal pain 1995 0 Myocardial infarction
5 Prothrombin mutation (20210) Ascites 2002 0 Myasthenia gravis
pseudoparalytica, Basedow
disease
6 Polycythemia vera Abdominal pain and
ascites
1998 1 Arterial hypertension
7 Polycythemia vera Abdominal pain and
ascites
1996 2 Arterial hypertension, Atrial
fibrillation
8 Antiphospholipid antibody
syndrome, APC resistance
Abdominal pain 1995 1 Deep venous thrombosis
9 Unknown Gastrointestinal
bleeding and ascites
2001 1 None
10 Protein C and AT III deficiency Abdominal pain 2005 0 None
11 APC resistance and AT III
deficiency
Abdominal pain and
ascites
2004 0 Atrial septal defect
12 Unknown Abdominal pain 1993 48 None
13 Oestrogen medication Abdominal pain and
ascites
2007 0 None
OLT Group
1 Polycythemia vera Abdominal pain 1988 12 None
2 Protein C and S deficiency Abdominal pain 2001 48 None
3 Unknown Ascites 2003 36 Sarcoidosis
4 Unknown Abdominal pain and
ascites
1992 24 Osteoporosis
Non-intervention Group
1 Myeloproliferative Disorder Acute liver failure 2005 None
2 Factor V (Leiden) mutation Abdominal pain and
ascites
2003 None
3 Essential thrombocythemia Abdominal pain 2003 None
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these 13 patients (85%) developed TIPS dysfunction
requiring reintervention. In most cases TIPS dysfunction
was due to thrombosis or pseudointimal hyperplasia and
could be managed by dilation. On average, 2.5 ± 2.2
revisions per patient were necessary (range: 0-8) (see
table 2). 12 out of 13 patients survived within the follow
up period (92%). One patient died in the course of the
underlying hematologic disease. After TIPS placement
no patient developed clinical relevant hepatic encephalo-
pathy. None of the patients in the TIPS group had to
undergo OLT subsequently.
After a mean of 30 ± 13 months after diagnosis
(range: 12-48 months) patients in the transplant group
underwent OLT. Each patient who underwent OLT as
initial therapy, had to undergo re-OLT. The first
patient had retransplantation within a few days
because of portal vein thrombosis and graft failure.
Today, 20 years after re-OLT she is still alive and has
an excellent graft function. The second patient had to
undergo 2 retransplantations. She had ischemic cho-
langiopathy in all explants and in the second explant
ischemic cholangiopathy in relation with arterial
thrombosis was found, histologically. The patient died
due to septic complications 3 months after the third
OLT. The third patient also had retransplantation
within a few days because of vascular obliteration of
the hepatic artery and a necrosis of the common bile
duct. This patient is still alive without further compli-
cations. The fourth patient had to undergo retrans-
plantation 9 months after initial OLT because of
ischemic graft failure. She is still alive 15 years after
OLT without limitations. Although no recurrence of
BCS in the transplants has been detected, each patient
in the transplant group suffered from various
thrombotic complications. Within the observation per-
iod 3 out of 4 patients survived (75%).
The overall probability of survival on an intention to
treat basis for the whole cohort of 20 patients with BCS
was 72.6% after a median follow-up of 5 years (range: 0
to 20 years), (see figure 1).
Discussion
In this study, we assessed the clinical course and long
term outcome of patients with BCS referred to our uni-
v e r s i t yh o s p i t a la n a l y s i n gt h ed a t ao fa l lp a t i e n t s
admitted with a primary diagnosis of BCS between 1988
and 2008.
Sequential use of increasingly invasive procedures
based upon the clinical response has been recommended
for the treatment of BCS [8,25,27]. In one study in 14
patients, treated with diuretics and anticoagulation
alone, a mortality rate of 86% during a period of 6
months was reported [36], however acceptable long
term survival rates with only medical therapy has been
reported in other trials [37]. Surprisingly, in the recently
published first prospective study [20] nearly 50% of the
patients were managed conservatively, too. But there
m a yb el i m i t a t i o n so ft h i ss t u d y ;o nt h eo n eh a n dt h e
study was not restricted to patients with severe disease
and on the other hand the median follow-up was only
17 months. In our present trial only 2 patients have not
had an invasive therapeutic procedure and are still with-
out clinical symptoms under anticoagulation therapy.
Both patients have incomplete hepatic venous outflow
obstruction and presented with chronic or subacute
BCS. In addition, in one of these two patients the fol-
low-up period of half a year is relatively short. On the
basis of this very limited experience, we may confirm
the value of medical treatment alone in patients with
Table 2 Angiographic findings and interventions in the TIPS group
Patient Angiographic findings* gradient reduction** Number of
additional Revisions
Follow up
1 HV, PV, SMV occluded 17 ® 8 2 2 years
2 HV occluded 30 ® 7 1 4 years
3 HV occluded 23 ® 10 3 2 years
4 HV occluded 29 ® 12 2 12 years
5 HV occluded 46 ® 6 1 5 years
6 HV, PV, IVC occluded 35 ® 6 8 7 years
7 HV occluded 32 ® 6 4 11 years
8 HV occluded 25 ® 10 1 3 years
9 HV occluded 20 ® 8 2 6 years
10 HV occluded 32 ® 3 0 3 years
11 HV occluded 31 ® 9 3 3 years
12 HV occluded 10 ® 4 6 10 years
13 HV occluded 38 ® 6 0 1/2 year
*HV: hepatic veins; PV: portal vein; SMV: superior mesenteric vein; IVC: inferior vena cava
**Numbers indicate original portosystemic pressure gradient followed by post-TIPS gradient in mmHg.
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disease or symptomatic cirrhosis, medical treatment was
not effective and interventional treatment (TIPS) or
transplantation had to be applied.
Different from the last Baveno consensus [26] treat-
ment was only partly applied in a stepwise manner. On
the basis of radiological imaging and the severity of clin-
ical presentation a decision concerning adequate treat-
ment was reached. In our collective 13 patients
underwent TIPS as initial therapy. In the follow-up, one
patient died in the course of the underlying hematologic
disease so that an overall survival of 92% was achieved.
In all patients transplantation could be avoided. Similar
5 year transplant free survival rates between 77 and
100% after TIPS were observed in other studies
[11-13,22-25]. These results seem to justify primary
TIPS treatment in patients with severe disease without
awaiting failure of a previous treatment step. Both the
high survival and the prevention of OLT in the patients
initially treated with TIPS demonstrate an advantage
over a stepwise strategy recommended by Baveno and
applied in the study by Plessier et al. [8]. Although, the
latter found high survival rates using therapeutic proce-
dures by order of increasing invasiveness, the need for
transplantation after TIPS w a sh i g h( 3 8 % )c o m p a r e dt o
our study. This may be due to the fact that TIPS is
more efficient when inserted early. Therefore, our
results suggest that TIPS should no longer be consid-
ered as a bridge to OLT but as a definitive treatment
option in BCS, especially when prompt intervention and
a high grade of interventional experience is available.
With regard to the current situation of liver donor
shortage these results are important.
Although, our protocol involved resumption of antic-
oagulation immediately after TIPS placement, 85% of
our patients had at least one reintervention within a
mean follow-up of 6 years. In all these patients TIPS
revision was technically successful and effective. How-
ever, TIPS dysfunction seems to be a common problem
[38,39]. Since, covered stents have a considerable advan-
tage over bare stents with a lower dysfunction rate for
the treatment of BCS patients [40], covered stents
should be preferred.
Four patients underwent OLT as initial therapy. Two
were transplanted before TIPS had been introduced as a
treatment option of BCS and two had cirrhosis with
signs of chronic liver failure. Survival following OLT
depends upon the underlying cause of BCS and the
patients condition at the time of transplantation [41]. A
large series with 510 patients [42] found a 3 year patient
survival of 85% after introduction of the Model for End-
Stage Liver Disease (MELD) score versus a 3 year
Figure 1 Probability of survival given for all BCS patients. On the x-axis the time of follow-up in years is given. On the y-axis the probability
of survival is shown.
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other studies [41,43] 10 year survival rates were reported
between 69 and 68%, respectively. It has been suggested,
that the outcome of OLT in BCS patients does not dif-
fer from that of other etiologies of liver failure when
adequate longterm anticoagulation is administered [44].
Even in patients with myeloproliferative diseases survival
rates are similar to those in patients with other underly-
ing etiologies [41]. Although, the number of patients
transplanted in the present trial does not allow any con-
clusions on survival, the overall survival rate of 75% dur-
ing a mean follow-up period of 11 years is comparable
to the reported results.
Each patient who underwent OLT as initial therapy,
had to undergo re-OLT, which is one of the most
important results of our study. All patients had graft
failure due to thrombotic or vascular complications.
These complications have been described in other series
and severe thrombotic complications occurred despite
routine early posttransplantation anticoagulation [8,41].
In accordance to other reports, these findings support
the concept that aggressive anticoagulation as early as
possible may reduce the risk of thrombembolic compli-
cations as well as the late recurrence of BCS after OLT
[41,43].
However, it seems likely, that in some cases throm-
bembolic complications will not be preventable, despite
of aggressive anticoagulation as observed in one patient
in our series.
Conclusion
In conclusion, therapy for BCS usually requires TIPS or
OLT. The treatment modality is dependent on duration
of illness, extent of thrombosis and degree of liver dys-
function. TIPS is successful as initial therapy as it pro-
motes clinical improvement in the long run even
though shunt revisions are generally needed. In the pre-
sent study the necessity of subsequent OLT was remark-
ably low and thus TIPS could be regarded as definitive
treatment option in BCS. OLT in BCS is associated with
an increased risk of thrombembolic complications and
early graft failure in spite of consequent anticoagulation
therapy.
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